Oral and upper gastrointestinal Crohn's disease

J Gastroenterol Hepatol. 2018 Feb;33(2):355-364. doi: 10.1111/jgh.13866.

Abstract

Crohn's disease is a heterogeneous, inflammatory condition that can affect any location of the gastrointestinal tract. Proximal gastrointestinal involvement occurs in 0.5-16% of patients, and it is usually diagnosed after recognition of intestinal disease. Symptoms are often mild and nonspecific; however, upper gastrointestinal disease predicts a more severe Crohn's phenotype with a greater frequency of complications such as obstruction and perforation. Gastroscopy and biopsy is the most sensitive diagnostic investigation. There is a paucity of data examining the treatment of this condition. Management principles are similar to those for intestinal disease, commencing with topical therapy where appropriate, progressing to systemic therapy such as glucocorticoids, 5-aminosalicylic acid, immunomodulators, and biologics. Acid suppression therapy has symptomatic but no anti-inflammatory benefit for gastroduodenal and esophageal involvement. Surgical intervention with bypass, strictureplasty, or less frequently, endoscopic balloon dilation may be required for complications or failed medical therapy.

Keywords: Crohn's disease; esophageal diseases; oral pathology; stomach diseases; upper gastrointestinal tract.

Publication types

  • Review

MeSH terms

  • Biological Products / therapeutic use
  • Crohn Disease / diagnosis
  • Crohn Disease / pathology
  • Crohn Disease / therapy*
  • Digestive System Surgical Procedures
  • Gastrointestinal Tract*
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use
  • Mesalamine / therapeutic use
  • Mouth*
  • Severity of Illness Index

Substances

  • Biological Products
  • Glucocorticoids
  • Immunologic Factors
  • Mesalamine